The anti-osteoporotic drug preferences of physiatrists: A multicenter descriptive study [Fiziatristlerin antiosteoporotik i·laç tercihleri: Çok merkezli tanimlayici araştirma]

Aim: The purpose of this multicenter descriptive study is to determine the preferences of physiatrists in our country for anti-osteoporotic drugs in patients with primary and secondary osteoporosis. Materials and Methods: This study was carried out in 10 provinces of Turkey. The diagnosis of osteoporosis was based on World Health Organization criteria using dual-energy x-ray absorptiometry. Patients with a spine and/or hip T-score ?-2.5 were considered as osteoporotic. 714 patients over 18 years old with primary or secondary osteoporosis were included in the study. In addition to socio-demographic characteristics and chronic use of medications and/or additional systemic diseases that cause secondary osteoporosis were questioned and antiosteoporotic drugs that are recommended by their physicians were recorded. Results: The physicians' preferred vitamin D and calcium as the prior treatment both in primary and secondary osteoporosis. The most commonly used anti-osteoporotic agent was alendronate from the biphosphonate group. It was followed by ibandronate, risedronate, strontium ranelate, calcitonin, zoledronate, raloxifene, parathyroid hormone (PTH) and hormone replacement therapy (HRT) in the primary osteoporosis and risedronate, ibandronate, calcitonin, strontium ranelate, zoledronate, PTH, HRT and raloxifene in the secondary osteoporosis, respectively. Conclusion: The physician should choose the most suitable treatment for the patient based on fracture risk, medical history, previous treatments for osteoporosis, concomitant diseases, treatment-induced risks and benefits, and the relation between financial cost and potential benefit.

Yazar Kutsal Y.G.
Oz¨demir O.
Çalişkan A.
Inanici F.
Karahan S.
Dogan A.
Hizmetli S.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/7845
Tek Biçim Adres 10.4274/tod.63634
Konu Başlıkları Medicine
Osteoporosis
Treatment
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
Dergi Adı Turk Osteoporoz Dergisi
Dergi Cilt Bilgisi 18
Dergi Sayısı 2
Sayfalar 42 - 46
Yayın Yılı 2012
Eser Adı
[dc.title]
The anti-osteoporotic drug preferences of physiatrists: A multicenter descriptive study [Fiziatristlerin antiosteoporotik i·laç tercihleri: Çok merkezli tanimlayici araştirma]
Yazar
[dc.contributor.author]
Kutsal Y.G.
Yazar
[dc.contributor.author]
Oz¨demir O.
Yazar
[dc.contributor.author]
Çalişkan A.
Yazar
[dc.contributor.author]
Inanici F.
Yazar
[dc.contributor.author]
Karahan S.
Yazar
[dc.contributor.author]
Dogan A.
Yazar
[dc.contributor.author]
Hizmetli S.
Yayın Yılı
[dc.date.issued]
2012
Yayıncı
[dc.publisher]
Galenos Yayincilik,
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Aim: The purpose of this multicenter descriptive study is to determine the preferences of physiatrists in our country for anti-osteoporotic drugs in patients with primary and secondary osteoporosis. Materials and Methods: This study was carried out in 10 provinces of Turkey. The diagnosis of osteoporosis was based on World Health Organization criteria using dual-energy x-ray absorptiometry. Patients with a spine and/or hip T-score ?-2.5 were considered as osteoporotic. 714 patients over 18 years old with primary or secondary osteoporosis were included in the study. In addition to socio-demographic characteristics and chronic use of medications and/or additional systemic diseases that cause secondary osteoporosis were questioned and antiosteoporotic drugs that are recommended by their physicians were recorded. Results: The physicians' preferred vitamin D and calcium as the prior treatment both in primary and secondary osteoporosis. The most commonly used anti-osteoporotic agent was alendronate from the biphosphonate group. It was followed by ibandronate, risedronate, strontium ranelate, calcitonin, zoledronate, raloxifene, parathyroid hormone (PTH) and hormone replacement therapy (HRT) in the primary osteoporosis and risedronate, ibandronate, calcitonin, strontium ranelate, zoledronate, PTH, HRT and raloxifene in the secondary osteoporosis, respectively. Conclusion: The physician should choose the most suitable treatment for the patient based on fracture risk, medical history, previous treatments for osteoporosis, concomitant diseases, treatment-induced risks and benefits, and the relation between financial cost and potential benefit.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
tur
Konu Başlıkları
[dc.subject]
Medicine
Konu Başlıkları
[dc.subject]
Osteoporosis
Konu Başlıkları
[dc.subject]
Treatment
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
2146-3816
İlk Sayfa Sayısı
[dc.identifier.startpage]
42
Son Sayfa Sayısı
[dc.identifier.endpage]
46
Dergi Adı
[dc.relation.journal]
Turk Osteoporoz Dergisi
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
18
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.4274/tod.63634
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/7845
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
24
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
16 Şubat 2024 13:59
Google Kontrol
Tıklayınız
osteoporosis secondary primary hormone physicians calcitonin ibandronate and/or strontium ranelate risedronate raloxifene diseases patients anti-osteoporotic treatment zoledronate Results preferred vitamin calcium followed biphosphonate alendronate commonly respectively parathyroid history benefit potential financial between relation benefits treatment-induced
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms